Video
Dr. Ornstein on efficacy and safety of sacituzumab govitecan for urothelial cancer
Author(s):
Video Player is loading.
Moshe Ornstein, MD, MA, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) for patients with urothelial cancer. The ADC is FDA-approved for the treatment of patients with locally advanced or metastatic urothelial cancer previously treated with chemotherapy and a PD-1/PD-L1 inhibitor.
Related Videos
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Study data point to gender disparities in oncology research citations
Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
Expert describes implications of neoadjuvant durvalumab approval in MIBC
Sima Porten, MD, on gene-environment interactions in bladder cancer development
How rBCG EAP could open up access for Anktiva in bladder cancer
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Joshua J. Meeks, MD, PhD, discusses the impact of neoadjuvant durvalumab approval in MIBC
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Related Content
